SCH-202,596

SCH-202,596

SCH-202,596 is a pharmacological compound that belongs to the class of PDE5 inhibitors. It was developed by Schering-Plough, a pharmaceutical company, for the potential treatment of erectile dysfunction and pulmonary arterial hypertension. However, the development of SCH-202,596 was discontinued and it never reached the market.

History

SCH-202,596 was first synthesized by Schering-Plough in the late 1990s as part of their research into PDE5 inhibitors. The compound showed promising results in preclinical trials, demonstrating the ability to inhibit the phosphodiesterase type 5 enzyme, which is involved in the regulation of blood flow in the penis and lungs.

Pharmacology

SCH-202,596 is a selective inhibitor of the phosphodiesterase type 5 enzyme. This enzyme is responsible for the breakdown of cyclic guanosine monophosphate (cGMP), a molecule that plays a crucial role in the relaxation of smooth muscle tissue. By inhibiting PDE5, SCH-202,596 increases the levels of cGMP, leading to the relaxation of smooth muscle tissue in the penis and lungs, and thus improving blood flow.

Clinical Trials

Despite the promising preclinical results, the development of SCH-202,596 was discontinued before it reached clinical trials. The reasons for this are not publicly disclosed, but it is speculated that the decision was influenced by the competitive landscape of the PDE5 inhibitor market, dominated by drugs such as sildenafil (Viagra) and tadalafil (Cialis).

See Also

• Phosphodiesterase type 5 inhibitors
• Erectile dysfunction
• Pulmonary arterial hypertension
• Schering-Plough

This article is a stub related to pharmacology. You can help WikiMD by expanding it!